Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Allows MDRNA Patent on Peptides for Delivery to Lung

Premium

MDRNA said this week that the US Patent and Trademark Office has allowed a company patent application covering "methods for the delivery of a broad array of compounds with pharmacological activity, including siRNAs, using proprietary targeting peptides that have preferential binding affinity for lung tissue."

The application, No. 20070197444, is entitled, "Phage-Displayed Cell-Binding Peptides," and claims "a tryptophan cage-binding domain polypeptide containing of all or part of [a defined] amino acid sequence," according to its abstract.

"This technology is directly applicable to the company's DiLA2 [drug-delivery] platform as peptides are readily conjugated to the amino acid scaffold of a DiLA2" molecule, MDRNA said. "Peptides capable of directed delivery are expected to further improve the delivery efficiency of UsiRNAs, which have demonstrated significant knockdown of target genes in mouse models of liver and bladder cancer, and in non-human primates."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.